Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials

PURPOSE: A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future phase 3 trial. METHODS: Serum concentration data wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hong, Liu, Lucy, Gao, Yuying, Ahene, Ago, Collins, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484135/
https://www.ncbi.nlm.nih.gov/pubmed/34383128
http://dx.doi.org/10.1007/s00280-021-04333-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484135/
https://www.ncbi.nlm.nih.gov/pubmed/34383128
http://dx.doi.org/10.1007/s00280-021-04333-y

Ejemplares similares